NATTO: OPTIONS GRANTED
Based on the power of attorney granted at the annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on May 20th, 2016, and the option program related to defined operative objectives approved by the Board of Directors in 2016, the Board of Directors of NattoPharma has in board proceedings February 7th, 2017 granted a total of 315 000 options to executive management and other employees. Options awards are granted based on performance against defined criteria and metrics.
The following persons on the executive management team have been granted options;
|Name||Position / Function||Granted Options||Options prior to grant||Options after grant|
|Daniel H Rosenbaum||CEO||88 000||75.000||163 000|
|Kjetil Ramsøy||CFO||32 000||37.500||69 500|
Other employees have been granted a total of 195 000 options.
The options have an exercise price equal the closing price on Oslo Axess on February 7th 2017, which is equal to NOK 11,20. The options granted are vested immediately, and may be exercised up to and including March 31st 2022.
* * *
For more information, please contact:
Kjetil Ramsøy, Chief Financial Officer
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.